Myocardial blood flow and flow reserve in response to hormone therapy in postmenopausal women with risk factors for coronary disease

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 6, 2004, Pages 2783-2788

  Duvernoy, C ^a,b,e   Martin, J ^a   Briesmiester, K ^a   Bargardi, A ^b   Muzik, O ^c   Mosca, L ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMMONIA; CONJUGATED ESTROGEN; GESTAGEN; NITROGEN 13; PLACEBO; PROGESTERONE;

ADRENERGIC STIMULATION; ADULT; AGED; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COLD PRESSOR TEST; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DRUG MECHANISM; ENDOTHELIUM; FEMALE; FLOW RATE; HEART MUSCLE BLOOD FLOW; HORMONAL THERAPY; HUMAN; INFUSION; MENOPAUSAL SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REST; TREATMENT OUTCOME;

AGED; AMMONIA; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; CROSS-OVER STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MICROCIRCULATION; MIDDLE AGED; NITROGEN RADIOISOTOPES; POSTMENOPAUSE; PROGESTERONE; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EQUIDAE;

EID: 2942683377     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031674     Document Type: Conference Paper

References (29)

1. Schachinger V, Britten MB, Zeiher AM 2000 Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899-1906
2. Zeiher A, Drexler H, Wollschlaeger H, Saurbier B, Just J 1989 Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. J Am Coll Cardiol 14:1181-1190
3. Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT, Mulvany MJ 2001 Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 104:2305-2310
4. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE 1994 Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24:471-476
5. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA 1994 Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 89:52-60
6. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 280:605-613
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
8. Gerhard M, Walsh B, Tawakol A, Haley E, Creager S, Seely E, Ganz P, Creager M 1998 Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 98:1158-1163
9. The Writing Group for the PEPI Trial 1995 Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273:199-208
10. 13N-labeled L-glutamic acid. Radiology 116:127
11. Duvernoy C, Rattenhuber J, Seifert-Klauss V, Bengel F, Meyer C, Schwaiger M 2001 Myocardial blood flow and flow reserve in response to short-term combined cyclical hormone replacement therapy in postmenopausal women. J Gend Specif Med 4:21-27
12. Sawada S, Muzik O, Beanlands RS, Wolfe E, Hutchins GD, Schwaiger M 1995 Interobserver and interstudy variability of myocardial blood flow and flow-reserve measurements with nitrogen 13 ammonia-labeled positron emission tomography. J Nucl Cardiol 2:413-422
13. Campisi R, Czernin J, Schoder H, Sayre JW, Schelbert HR 1999 L-Arginine normalizes coronary vasomotion in long-term smokers. Circulation 99:491-497
14. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB 1998 Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847
15. Gilligan DM, Quyyumi AA, Cannon R 1994 Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89:2545-2551
16. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon R 1994 Acute vascular effects of estrogen in postmenopausal women. Circulation 90:786-791
17. Riedel M, Mugge A 1994 Direct effects of estrogens on vascular tone: characterization and clinical significance. Z Kardiol 83:768-774
18. Rouleau JR, Dagnault A, Simard D, Lavallee B, Belanger A, Blouin A, Kingma Jr JG 2001 Effect of estrogen replacement therapy on distribution of myocardial blood flow in female anesthetized rabbits. Am J Physiol 281: H1407-H1412
19. Clark KE, Baker RS, Lang U 2000 Premarin-induced increases in coronary and uterine blood flow in nonpregnant sheep. Am J Obstet Gynecol 183:12-17
20. Hirata K, Shimada K, Watanabe H, Muro T, Yoshiyama M, Takeuchi K, Hozumi T, Yoshikawa J 2001 Modulation of coronary flow velocity reserve by gender, menstrual cycle and hormone replacement therapy. J Am Coll Cardiol 38:1879-1884
21. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu CR, Liu CH, Azen SP 2001 Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135:939-953
22. Herrington DM, Espeland MA, Crouse 3rd JR, Robertson J, Riley WA, McBurnie MA, Burke GL 2001 Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol 21:1955-1961
23. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM 1994 Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 89:1501-1510
24. Campisi R, Nathan L, Pampaloni MH, Schoder H, Sayre JW, Chaudhuri G, Schelbert HR 2002 Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration. Circulation 105:425-430
25. Di Carli MF, Afonso L, Campisi R, Ramappa P, Bianco-Batlles D, Grunberger G, Schelbert HR 2002 Coronary vascular dysfunction in premenopausal women with diabetes mellitus. Am Heart J 144:711-718
26. Schindler TH, Nitzsche EU, Munzel T, Olschewski M, Brink I, Jeserich M, Mix M, Buser PT, Pfisterer M, Solzbach U, Just H 2003 Coronary vasoregulation in patients with various risk factors in response to cold pressor testing: contrasting myocardial blood flow responses to short- and long-term vitamin C administration. J Am Coll Cardiol 42:814-822
27. Nagamachi S, Czernin J, Kim AS, Sun KT, Böttcher M, Phelps ME, Schelbert HR 1996 Reproducibiliry of measurements of regional resting and hyperemic myocardial blood flow assessed with PET. J Nucl Med 37:1626-1631
28. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK 1997 Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 17:217-221
29. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K 1997 Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 3:324-327